Pharmacokinetic Properties of Rasagiline (Lu 00-773) in Healthy Young Chinese Men and Women
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to fulfil regulatory requirements for registration of a new
chemical entity in China. Rasagiline is approved for the treatment of Parkinson's Disease
(PD) in Europe and the US. Rasagiline is safe and well tolerated in healthy subjects, and the
efficacy and safety has been demonstrated in placebo- and active comparator-controlled phase
III studies.